FDMT 4D MOLECULAR THERAPEUTICS IN
2026Q2 · CUSIP 35104E100 · Sector: Healthcare & Biotech
Fund flows are within the usual range
158 funds held FDMT at the end of 2026Q2, up 12 from the quarter before. Fund flows are within the usual range — nothing unusual. On the business itself, return on equity is -44.0%. FDMT has had 3 buying rushes in its history, and the price moved +62.2% on average over the six months after (that is the raw price move, not how much it beat the market by). It sits in the Healthcare & Biotech sector.
How many funds owned it, quarter by quarter
Bars = net change in institutional holders, positive (green) or negative (red). Line = total institutional holders.
What happened after each past buying rush 3 times in its history
| Quarter of the rush | How unusual then | Price, next 3 months | Price, next 6 months |
|---|---|---|---|
| 2024Q1 | Top 10% | -41.9% | -65.2% |
| 2023Q3 | Top 20% | +148.3% | +135.7% |
| 2022Q2 | Top 20% | +108.8% | +116.0% |
These are the raw price moves, not how much it beat the market by. Compare them against the market over the same months — in a strong bull market almost everything is up.
Show all the numbers (large funds, value held, options…) ▾ Collapse ▴
These are for people who want to dig. Skip them if they do not mean anything to you — the three numbers above are enough.
8,697 institutions have filed for this quarter. 13F permits late filing and a small number arrive in the weeks after the deadline, so the holder counts and changes below may tick up.
Fundamentals
Quarterly figures, revenue up to 10 years back; EPS split-adjusted, early quarters hidden when not calibrable
FCF = operating cash flow − capex, computed from SEC XBRL; banks/insurers have no standard cash-flow structure and are hidden
As of 2026-06-30 · SEC filings (XBRL)
Email me the next update
2026 Q3 holdings are due 2026-11-16. We will email you when the refreshed lists are live.